The use of temporary mechanical circulatory support in cardiogenic shock has increased
dramatically despite a lack of randomized controlled trials or evidence guiding clinical …

Cardiogenic shock can occur due to acute ischaemic or non-ischaemic cardiac events, or
from progression of long-standing underlying heart disease. When addressing the cause of …

Cardiogenic shock (CS) remains the most common cause of mortality in patients with acute
myocardial infarction. The SHOCK trial (Should We Emergently Revascularize Occluded …

Abstract Purpose of Review Ischemic cardiomyopathy refers to systolic left ventricular
dysfunction in the setting of obstructive coronary artery disease and represents the most …

Objective The DanGer Shock trial test the hypothesis that left ventricular (LV) mechanical
circulatory support with Impella CP transvalvular microaxial flow pump improves survival in …

There has been a significant increase in the use of short-term percutaneous ventricular
assist devices (pVADs) as acute circulatory support in cardiogenic shock and to provide …

Interest in the use of mechanical circulatory support for patients presenting with cardiogenic
shock is growing rapidly. The Impella (Abiomed Inc), a microaxial, continuous-flow, short …

The Impella device (Impella, Abiomed, Danvers, MA) is a percutaneous transvalvular
microaxial flow pump that is currently used for (1) cardiogenic shock,(2) left ventricular …

See page 49 for disclosure information. List of abbreviations: ACT, activated clotting time;
aPTT, activated partial thromboplastin time; ACHD, adult congenital heart disease; ADHF …

Originally intended for life-saving salvage therapy, the use of temporary mechanical
circulatory support (MCS) devices has become increasingly widespread in a variety of …